Cardiac effects of amiselimod compared with fingolimod and placebo: results of a randomised, parallel‐group, phase I study in healthy subjects

Harada, Tomohiko; Wilbraham, Darren; de La Borderie, Guillemette; Inoue, Shinsuke; Bush, Jim; John Camm, A.

doi:10.1111/bcp.13203

Public

Cardiac effects of amiselimod compared with fingolimod and placebo: results of a randomised, parallel‐group, phase I study in healthy subjects

Published in British Journal of Clinical Pharmacology • Dec 6, 2016

Authors:

Tomohiko Harada

Darren Wilbraham

Guillemette de La Borderie

Abstract

AIM: ) receptor modulator which is currently being developed for the treatment of various autoimmune diseases. Unlike some other S1P receptor modulators, amiselimod seemed to show a favourable cardiac safety profile in preclinical, phase I and II studies. The aim of the current study was to characte...

Subject

Fingolimod

Chronotropic

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!